Access

Format

Author / Creator

Subject

Recently added

Eresources

Language

Place of Publication

Dates

Location

Americo Agostino / Alfredo Flores

George Barnes / Marshall Clayton
George Barnes / Freddie Dawson
George Barnes / George Kapeen
George Barnes / Pran Mikus

Carmine Basilo / Chuck Davey

Elley Bennett / Luis Castillo
Elley Bennett / Cecil Schoonmaker

Joey Brown / Irvin Steen
Al Bourke / Ron Toohey

Tommy Burns / George Barnes
Tommy Burns / O'Neill Bell
Tommy Burns / Hockey Bennell
Tommy Burns / Len Dittmar
Tommy Burns / Don Johnson
Tommy Burns / Eddie Marcus
Tommy Burns / Pran Mikus
Tommy Burns / Mickey Tollis

Jimmy Carter / Charlie Ashenden
Jimmy Carter / Lauro Salas

Ezzard Charles / Nick Barone
Ezzard Charles / Frankie Buford
Ezzard Charles / Gus Lesnevich
Ezzard Charles / Joey Maxim
Ezzard Charles / Lee Oma
Ezzard Charles / Pat Valentino
Ezzard Charles / Joe Walcott (2)

Alfie Clay / George Barnes
Alfie Clay / Jackie Debelin
Alfie Clay / Bernie Grant
Alfie Clay / Dave Landers
Alfie Clay / Pierre Montane (glass)
Alfie Clay / Babe Ortiz

Ray Coleman / Alfie Webster

Gerald Dreyer / Barry Brown

Don Johnson / Elma Berzinkis (glass)

Vic Patrick / Freddie Dawson (3) (glass)

Unidentified (2)

Michael J Clarke boxing negatives. Box 15: Action (1)

The great picture : making the world's largest photograph : the Legacy Project, Jerry Burchfield, Mark Chamberlain, Jacques Garnier, Rob Johnson, Douglas McCulloh, Clayton Spada / text by Dawn Hassett.

Taking stock, feminism reviewed : Gullivera's travails / by Irene Irvine.

Part A: Bookplates filed alphabetically by the owner of the bookplate, "A to O", 1891-1935

Sub-series 1: Angus & Robertson book reviews in bound volumes, 1894-1970

Abstract
Background
Interleukin 6 (IL-6) plays important roles in both innate and adaptive immunity, while dysregulated persistent production of IL-6 is involved in pathological development of various diseases associated with inflammation. Targeting the IL-6 pathway has led to many innovative treatment approaches. Siltuximab and Tocilizumab are monoclonal antibodies targeting IL-6 and IL-6 receptors respectively and have been FDA-approved for treatment of Castleman disease (Siltuximab), a rare lymphoproliferative disorder characterized by hyperproduction of IL-6 with an unknown prevalence, autoimmune diseases such as rheumatoid arthritis (Tocilizumab), and both shown potential as treatment for cytokine release syndrome in hospitalized COVID-19 patients. However, the presence of siltuximab can interfere with IL-6 assays, leading to the use of C-reactive protein (CRP) as a surrogate marker to monitor its efficacy.
Aim
To evaluate potential Siltuximab and Tocilizumab antibody interference on IL-6 measurements in three different IL-6 protein immunoassays. Method: Serum or EDTA plasma sample pools with different IL-6 concentrations ranging from low (2.3 – 11.1 pg/mL, around the reference interval cut-off for each assay) to high (18.5 – 1142 pg/mL), above reference interval cut-off for each assay) were utilized. Various concentrations of Siltuximab or Tocilizumab were spiked into the sample pools (at 10% of total volume) to achieve final concentrations up to 600 µg/mL and up to 300 µg/mL, respectively. Sample spiked with 10% saline were used as no-drug control. Three assays were used to measure IL-6 concentration: Beckman Access IL-6 assay on UniCel DxI 800 (Beckman Coulter), V-PLEX Plus human IL-6 assay on QuickPlex SQ120 (Meso Scale Diagnostics), and a Luminex cytokine panel assay developed in house (R&D systems) with upper reference interval limits of 6.4,1.8 and 5 pg/mL respectively.
Results
Siltuximab interfered with the measurement of IL-6 for all three assays. A significant interference (> 20% reduction) was observed at even a very low siltuximab concentrations in all three assays (0.05 µg/mL). In the presence of 5 µg/mL or greater Siltuximab, a maximum reduction of 93%, 83%, and 40% was observed for Beckman Access, R&D Luminex assay, and V-PLEX Plus Mesoscale assay, respectively. Tocilizumab did not interfere with the measurement of IL-6 in the three assays when serum was spiked with up to 300 µg/mL of the drug.
Conclusion
Siltuximab falsely reduce the measured IL-6 concentration on all three immunoassays tested in this study to differing degrees, whereas Tocilizumab does not. Consider the therapeutic range of Siltuximab (84 to 332 µg/mL) for treatment of Castleman disease, and a half-life of 20.6 days, measurement of IL-6 may not be useful in Siltuximab treated patients for an extended time-period.

American journal of clinical pathology, 2023-11, Vol.160 (Supplement_1), p.S123-S124

Evaluation of Siltuximab and Tocilizumab Analytical Interference on Interleukin 6 Measurements

Export record to excel

Export this record

Export record to excel

Michael J Clarke boxing negatives. Box 15: Action (1)

Export this record

Export record to excel

The great picture : making the world's largest photograph : the Legacy Project, Jerry Burchfield, Mark Chamberlain, Jacques Garnier, Rob Johnson, Douglas McCulloh, Clayton Spada / text by Dawn Hassett...

Export this record

Export record to excel

Taking stock, feminism reviewed : Gullivera's travails / by Irene Irvine.

Export this record

Export record to excel

Part A: Bookplates filed alphabetically by the owner of the bookplate, "A to O", 1891-1935

Export this record

Export record to excel

Sub-series 1: Angus & Robertson book reviews in bound volumes, 1894-1970

Export this record

Export record to excel

Evaluation of Siltuximab and Tocilizumab Analytical Interference on Interleukin 6 Measurements

Refine your search